Neuropeptide Y Y2 receptor signalling mechanisms in the human glioblastoma cell line LN319.
Neuropeptide Y (NPY) regulates neurotransmitter release through activation of the Y2 receptor subtype. We have recently characterized a human glioblastoma cell line, LN319, that expresses exclusively NPY Y2 receptors and have demonstrated that NPY triggers transient decreases in cAMP and increases in intracellular calcium responses. The present study was designed to further characterize calcium signalling by NPY and bradykinin (BK) in LN319 cells. Both agonists elevated free intracellular calcium ([Ca(2+)](i)) without soliciting calcium influx. NPY appeared to activate two distinct signalling cascades that liberate calcium from thapsigargin- and ryanodine-insensitive compartments. One pathway proceeded through phospholipase C (PLC)-dependent phosphatidylinositol turnover, while the other triggered calcium release through a so far unidentified mediator. Part of the response was sensitive to pertussis toxin (PTX) under conditions where the toxin totally abolished the NPY-mediated effects on cAMP. The calcium release induced by BK on the other hand was largely PTX-insensitive, PLC-dependent, and from both thapsigargin- and ryanodine-sensitive stores. Following stimulation with NPY, subsequent [Ca(2+)](i) responses to NPY were strongly depressed. Partial heterologous desensitization occurred, when BK was used as the first agonist, whereas NPY had no effect on a subsequent stimulation with BK. These data suggest that NPY-induced calcium mobilization in LN319 cells involves two different G proteins and signalling mediators, and a hitherto unidentified calcium compartment. Homologous desensitization of NPY signalling might be explained by receptor-G protein uncoupling, while heterologous desensitization by BK could be the result of either transient depletion or inhibition of a mediator in the calcium signalling cascades activated by NPY.
Grouzmann
E
E
Division of Hypertension, Lausanne University Hospital, 1011, Lausanne, Switzerland. eric.grouzmann@chuv.hospvd.ch
Meyer
C
C
Bürki
E
E
Brunner
H
H
D000818:Animals; D001920:Bradykinin / Q000494:pharmacology; D001932:Brain Neoplasms / Q000378:metabolism*; D002118:Calcium / Q000494:pharmacology; D000242:Cyclic AMP / Q000378:metabolism; D004963:Estrenes / Q000494:pharmacology; D019204:GTP-Binding Proteins / Q000378:metabolism; D005909:Glioblastoma / Q000378:metabolism*; D006801:Humans; D007295:Inositol Phosphates / Q000378:metabolism; D009478:Neuropeptide Y / Q000494:pharmacology; D037342:Pertussis Toxin; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology; D011485:Protein Binding; D011760:Pyrrolidinones / Q000494:pharmacology; D017476:Receptors, Neuropeptide Y / Q000737:chemistry* / Q000378:metabolism*; D012433:Ryanodine / Q000378:metabolism; D015398:Signal Transduction; D013552:Swine; D019284:Thapsigargin / Q000378:metabolism / Q000494:pharmacology; D014407:Tumor Cells, Cultured; D010738:Type C Phospholipases / Q000378:metabolism; D010566:Virulence Factors, Bordetella / Q000494:pharmacology
D004963:Estrenes; D007295:Inositol Phosphates; D009478:Neuropeptide Y; D010726:Phosphodiesterase Inhibitors; D011760:Pyrrolidinones; D017476:Receptors, Neuropeptide Y; D010566:Virulence Factors, Bordetella; C095889:neuropeptide Y2 receptor; C060229:1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione; D012433:Ryanodine; D019284:Thapsigargin; D000242:Cyclic AMP; D037342:Pertussis Toxin; D010738:Type C Phospholipases; D019204:GTP-Binding Proteins; D001920:Bradykinin; D002118:Calcium